The 1st World Congress on Controversies in Hematology (COHEM)
Rome, Italy, 2-5 September, 2010
Congress Presentations
Friday, September 3, 2010
Session 2: ACUTE MYELOID LEUKEMIA (AML) I Should the therapy of AML be driven by MRD quantification?
Yes: S. Amadori
Novartis Satellite Symposium: CURRENT PROGRESS IN CML THERAPY Nilotinib: A selective choice for resistant and Intolerant patients to Imatinib
M. Breccia
Session 3: ACUTE MYELOID LEUKEMIA (AML) II and ACUTE PROMYELOCYTIC LEUKEMIA (APL) Do we require chemotherapy to cure APL?
Yes: M.A. Sanz
No: F. Lo-Coco
Can novel prognostic markers predict for success and guide therapy in AML?
Yes: D. Grimwade
No: A. Burnett
Session 4: ACUTE LYMPHATIC LEUKEMIA (ALL) Is the efficacy of the pediatric-like protocols for ALL superior to the protocols for adult ALL?
No: J.M. Ribera
Session 5: CHRONIC LYMPHATIC LEUKEMIA (CLL) Is eradication of MRD feasible and worthwhile in CLL?
Yes: G. Marti
No: G. Gaidano
Is the “wait and watch” philosophy still practical in the treatment of CLL even in younger patients?
Yes: K. Rai
No: F. Caligaris-Cappio
Session 6: INDOLENT NON-HODGKIN LYMPHOMA (NHL) Is there a role for Rituximab in maintenance treatment in non-follicular indolent lymphomas?
Yes: A. Hagenbeek
Is molecular remission the goal in first line therapy of all patients with indolent non-Hodgkin lymphoma?
Yes: P. Corradini
Session 7: MULTIPLE MYELOMA (MM) Should therapy for newly diagnosed MM be risk adapted?
No: E. Terpos
Saturday, September 4, 2010
Session 8: STEM CELL TRANSPLANTATION (SCT) I How should we treat a 60 year old patient with Myelodysplastic syndrome?
Conventional Therapy: U. Platzbecker
Should all adult ALL patients have a stem cell transplantation in first remission or only high risk patients?
All: A. Goldstone
Session 9: STEM CELL TRANSPLANTATION (SCT) II Should CBT, Haploidentical transplant or MUD transplant be considered upfront if no sibling donor is available?
Haplo: M. Martelli
Should CBT, Haploidentical transplant or MUD transplant be considered upfront if no sibling donor is available?
Myeloablative: A. Rambaldi
Session 11: HODGKIN AND NON-HODGKIN LYMPHOMA Has PET/CT an established role in the management of HD and NHLs?
Yes: M. Hutchings
No: U. Vitolo
Does molecular outcome prediction in DLBCL add clinical value?
Yes: C. Gisselbrecht
Session 12: COAGULATION Is there still a role for splenectomy in ITP?
Yes: B. Godeau
Session 13: CHRONIC MYELOID LEUKEMIA (CML) I Is mutation analysis of BCR ABL of any value in clinical management of CML patients?
No: D. Marin
Session 14: CHRONIC MYELOID LEUKEMIA (CML) II Can we eventually stop TKI in all CML patients?
No: J. Goldman
Session 15: HEMOGLOBINOPATHIES & PNH Pros and cons of gene therapy in beta-thalassemia
Lecture: S. Rivella
How far one should go with iron chelation in thalassemia? Is iron deficiency indicated?
Yes: V. Berdoukas
Do the benefits of complement blockade extend to all patients with PNH clone?
Yes: A.M. Risitano
Sunday, September 5, 2010
Session 16: MYELO PROLIFERATIVE NEOPLAMS (MPNs) Are JAK2 positive PV, ET and IM different diseases?
No: A.M. Vannucchi
Yes: W. Vainchenker
Do JAK2 inhibitors represent a major advance in the treatment of myeloproliferative neoplasms?
No: T. Barbui
Session 17: INFECTIONS Is there a role for empirical or pre-emptive antifungal treatment in patients with hematological malignancies?
Yes: B. de Pauw
Is monitoring of azole concentrations of clinical value in pts with hematological malignancies?
No: P. Donnelly
Session 18: PLENARY SESSION Is there a role of biologic prognostic markers in the treatment of CLL?
Against: K. Rai
Are there sufficient indications for switching to new anticoagulant agents?
For: M.M. Samama
Which is the best chemotherapy regimen in Hodgkin Lymphoma?
ABVD: A. Levis
BEACOPP: V. Diehl
Is chemotherapy alone sufficient for the treatment of Hodgkin Lymphoma?
WebStudio.co.il